"Tetrahydrofolate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the reaction 7,8-dihyrofolate and NADPH to yield 5,6,7,8-tetrahydrofolate and NADPH+, producing reduced folate for amino acid metabolism, purine ring synthesis, and the formation of deoxythymidine monophosphate. Methotrexate and other folic acid antagonists used as chemotherapeutic drugs act by inhibiting this enzyme. (Dorland, 27th ed) EC 126.96.36.199.
- Tetrahydrofolate Dehydrogenase
- Dehydrogenase, Tetrahydrofolate
- Folic Acid Reductase
- Acid Reductase, Folic
- Reductase, Folic Acid
- Dihydrofolate Dehydrogenase
- Dehydrogenase, Dihydrofolate
- Dihydrofolate Reductase
- Reductase, Dihydrofolate
Below are MeSH descriptors whose meaning is more general than "Tetrahydrofolate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydrofolate Dehydrogenase".
This graph shows the total number of publications written about "Tetrahydrofolate Dehydrogenase" by people in this website by year, and whether "Tetrahydrofolate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Tetrahydrofolate Dehydrogenase" by people in Profiles.
Zhu WY, Bunni M, Priest DG, DiCapua JL, Dressler JM, Chen Z, Melera PW. Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells. J Exp Ther Oncol. 2002 Sep-Oct; 2(5):264-77.
Tapiero H, Tew KD, Gaté L, Machover D. Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements. Biomed Pharmacother. 2001 Sep; 55(7):381-90.
Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol. 2000 May; 20(10):3633-9.
Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, Fan J, Banerjee D, Bertino JR. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst. 1996 Sep 18; 88(18):1269-75.
Pizzorno G, Moroson BA, Cashmore AR, Russello O, Mayer JR, Galivan J, Bunni MA, Priest DG, Beardsley GP. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res. 1995 Feb 01; 55(3):566-73.
Bratoeva MP, John JF. In vivo R-plasmid transfer in a patient with a mixed infection of shigella dysentery. Epidemiol Infect. 1994 Apr; 112(2):247-52.
Ledbetter JW, Pfleiderer W, Freisheim JH. Laser-sensitized tautomers in dihydrofolate reductase. Adv Exp Med Biol. 1993; 338:499-502.
Fukumoto M, Roninson IB. Detection of amplified sequences in mammalian DNA by in-gel renaturation and SINE hybridization. Somat Cell Mol Genet. 1986 Nov; 12(6):611-23.
Varshavsky A, Barsoum J, Roninson I, Snapka R. Acquisition and loss of amplified genes: dramatic effects of hormones, tumor promoters and cytotoxic drugs. Princess Takamatsu Symp. 1983; 14:235-54.
Priest DG, Ledford BE, Doig MT. Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cells. Biochem Pharmacol. 1980 Jun 01; 29(11):1549-53.